Clinical Trial Update: Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection [Phase 2]

View source ↗

Summary

Phase 2 trial updates on presatovir for hospitalized adults with RSV infection, focusing on efficacy, pharmacokinetics, and safety after study completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Presatovir (GS-5806)

Snippet

Sponsor: Gilead Sciences | Conditions: Respiratory Syncytial Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2018-05-11